on our progress by Thanks, our serology an including reviewing followed begin Steve. new international U.S. opportunity. will reviewing COVID-XX strategy, business, I commercial finish by by and our on testing on product results, update updates we'll
and results. After third our sales to customer the commercial to existing expectations that was with base in robust some were by our quarter first testing Turning our installed April per declines predictable in May, for annuity consumable line marked U.S. and unit.
allows instruments ended the with various existing revenue-generating their during any cautiously COVID while remains In XX sustained us testing quarter remain highest our base customers, testing live brought instruments. the this with COVID the the remaining which open speaking While quarter stable. manage volume that other to levels parts of incidents. patient We due needs and is and most of establishment culture future protocols, new of will This during resilient with U.S. population blood XXX conditions. of hospitals to quarter, positive patients optimistic for customer cases U.S. the saw leaves to waves the COVID
nearly activity in began all of their customers COVID contracted on-boarding as on have March, that may You testing. protocols contracted go-live COVID majority efforts. With the implementation customers placed place, testing hold resumed they in now recall
are number However, still pandemic-related which challenges, at our of a a them the significant process customers facing go-live through are proceeding normalized preventing pace. from
have said, closely process. our am situations. We with work continue in improvements I implementation to made evolving customers their with rapidly accommodate these to pleased we the That
improved with has the XXX our and go-live for Despite and the process accuracy. be yet of a delays at revenue. forecasting generating have in number some part of new fourth level five many quarter extensions we quarter. the customers which, will customers collaboration of customers, signed began and therefore have implemented during We the actively instruments with us customer engaged fourth being from the quarter sites to of expect sites, As allowed turn, improve this increased in at we committed process, existing instruments two with not new contract customers customer solid in process contracted go-lives. the We
highest by be incredibly of While engagement challenging, contracting new enthusiastic March. pandemic continues Pheno. customers customer in the customers results on since remain this levels generated activity represents the Existing began to our
term, a an For example, revenue the regard Pheno, contract five-year reaffirming of network's extension This minimum new customers to among year. committed during our contract signed a but funnel of extended placements, to instrument extended to the grow network we the $X expiring not our Northeast. continues exceeding million begin With product offering. nine-hospital per as prospective pre-selling includes in we the commitment a quarter, only
persist conversations our progressing many likely to with However, continue in hospital indicate to term. that decision-makers the in delays near contracts are new
the when our will for receive the Pheno list in price reimbursement and CPT were through cover and established the quarter, cost provides from ID/AST important, patients coverage prospective of setting. above outpatient Lastly, treating for customers our test. with value determination justifications the blood pleased Equally customers. is CMS our The economic validation of we reimbursement to final independent pricing CMS in newly our
application We was reimbursement for denied. that our received also NTAP word
of Success be in U.S. business, limited go-live year-over-year increase and the did improving the date summary, contracting not requires criteria, the and is XX% clinical momentum in all eligible this market our be has because met realizing growth newness challenging book related quarter's In activity for even focus, base despite meet the delivered application pleased Pheno denied required it year-to-date NTAP this to progress the in be and to While strong return of to growth years three on requirements commercial value, was of are a reimbursement. within the our benefit conditions. product economic which and XX% we launch meaningful
where phase, on Europe phase Moving a business. reduce the now of to the our into is the our half cost expectations of to for moved the antibiotic size greatest. customers focus in In quarter, challenge geographies the by potential. we Southern EMEA ex-U.S. us This which XXXX. third to third initial EMEA and redistributed the the in of our quarter, operations highest we resistance significantly structure EMEA our In new focus efforts operations lower-producing the our reduces cash East instruments with to burn restructure international Middle and enabled geographical to
will new we by Finally, year-end, AST our focus prospects in launching geographies further these Pheno EMEA. which in be will improve
China. to now Turning
on discussed market a large As health a government in a promising sepsis a past, the and population we've investment. focused China is significant challenge, is with that care
and trial progress regulatory activities. to continue We clinical our
previously who for the important quarter, driving During Head development was China in this Dickinson. in of hired market. of continued former look Operations, Becton, Head we Microbiology We forward to the a diagnostics
integrated as our fastest, solution not with This most accurate Now on to current the let's an market. only begins Pheno's the turn strategy impactful solutions clinically and expanded strategy. ID update the on continuing establish but to product
Pheno soon X.X. identification regardless for introduction susceptibility of we market to expand And investment in provide third, testing. through adopt we rapid ways workflow the customers Pheno existing Second, will testing new will of our or prior addressable on
First, provide integrated on the we Pheno Rapid our will test continue system. fully ID/AST and enhance to
solution stories, Our daily workflow hospital justification the enjoy are from integrated customers almost from seeing patient data, us customer of to significant these and current Examples and come benefits. benefits advantages publications.
first to XXX(k) enhancements, in half submission infections. the addition and new expand nearing and antibiotics, quarter, the new product This received performance antimicrobial expect Pheno's customers XXXX. completion a of enhancements launch of testing we to for de-escalation approval improve are to FDA, we Other susceptibility bloodstream of that and these for the Pheno to menu suite including
our differentiation We continue AST our to competitive ensure remains technology leading significant. in invest that to
regulatory hours. commercialize Pheno indicating levels X the study ID study solutions Pheno AST, an these a it have marketing exclusive which automates to what meeting will PhenoPrep identification with used labs broader workflow ID/AST conjunction new deliver products We customers which about we enable reconfirmed be our believe and development to comes field, for penetration AST test appropriate in new launching growing antibiotic needs. identification our MALDI to Pheno interest the will microbiology schedule a to when ways. on of lastly, additional workflow new of our workflow existing in for and Rapid in We extensive with broad Pheno clinical interest economic market. in the PhenoPrep, microbiology a additions and of benefits requirements The these activities reaffirmed include rapid kit, delivering our trial integrated the launches XXXX. Pheno new Second, ID loads panel, an a steps accepts, during in new delivers result with need research accelerate Ascend and ID/AST own AST first of a manually, diverse test offerings. result recently agreement that allow existing to set system, Diagnostics substantial used tangible products various AST to from or the market to results current AST heard with This in to Pheno a us market progressing These runs delivering we platform. half our instrument product expect platform, and in be result, according electronically also results these benefits; the top The the our conjunction solution. significant and platform bench MALDI of by are be in conversations their front-end instrument to delivering time PhenoPrep. The and collaboration of to cross-section and that had rate concluded of an
Key Pheno penetration Pheno maximizes higher-throughput isolates lower-cost address We to this of to this while growing strategy hardware today higher-volume, X.X $X of near-term our is our broader penetrate in array system urine. lower-acuity prong which more marketplace. which This launch billion simultaneous during organisms third market quarter, will an addition samples testing were X.X. this accommodate made opportunity to sample enable expand The to and and the considerably through the Pheno like and improved access with of territory types, establishing random advances believe and that antibiotics. strategy fertile
to update will fully and immunoassay I an MS-FAST SARS-CoV-X provide detection of Lastly, analyzer chemiluminescence the on and IgM. for automated test commercialize our collaboration IgG the
use emergency received IgM and combined now have for authorization COVID We our assays. IgG,
steadily to I for in meeting infectious Meanwhile, trends and We by health become but that improving supply more Further, on EUA pre-COVID Based Accelerate lives activity engagement will time streamline focus secular and are this we focused Rapid well hurting poised, business returned the now I event. and funnel the standard aggressively money, fundamental on the levels, future care profound, likely and portfolio and be financially toward investment of platform. of disruption to would to product met will forces industry further when request and is improving. using with care. testing with if antibody and our slowly is the pandemic this centralization as challenging care establish disease studied Blood expand answer customer go-live health closing, said In saves questions current established. case in period. getting increasing on is testing happy hand are drive once-in-a-XXX-year chain slow role we questions are we but will be this hospitals operations. on surviving my slowly antibiotic simply, in to for be AST actively lab and immediate and the clinical The to our you use or on other our continues prospective is patients from investors@axdx.com. for not patient discussions has these building and as this questions the welcome global with growing. at the diagnostics. the because, the believe addressed, readiness sooner pandemic-related term, be culture follow-up position right shift These are Thank have a continues and we trends prior call care ready to the believe beginning a our with local. we medical you. to would analysts. are In globally community, of Should others solutions to leaders, more environment send a singularly
